Last updated: February 22, 2026
What is the drug represented by NDC 71288-0503?
NDC 71288-0503 corresponds to Brolucizumab (Beovu), a vascular endothelial growth factor (VEGF) inhibitor approved for the treatment of neovascular age-related macular degeneration (AMD). It is administered via intravitreal injection.
Market Overview
Current Market Size
The global AMD drug market was valued at approximately $4.3 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 4.8% through 2030 (Grand View Research). Beovu holds a significant share within the anti-VEGF segment, competing primarily with:
- Ranibizumab (Lucentis)
- Aflibercept (Eylea)
- Brolucizumab (Beovu)
Competitive Position
Brolucizumab was approved by the FDA in October 2019. Its advantages include lower dosing frequency, which appeals to both clinicians and patients. Current competition is characterized by:
| Drug |
Company |
Dosing Frequency |
Approved Indications |
Price (per injection) |
| Beovu (71288-0503) |
Novartis |
Every 12 weeks after 3 monthly doses |
Neovascular AMD |
~$1,850 |
| Eylea |
Regeneron |
Every 8-12 weeks |
AMD, Diabetic Retinopathy |
~$1,850 |
| Lucentis |
Genentech |
Monthly |
AMD, Diabetic Retinopathy |
~$2,000 |
Market Penetration
By mid-2022, Beovu accounted for approximately 15-20% of the anti-VEGF AMD market share in the U.S., with growth driven by its dosing schedule and clinical outcomes.
Regulatory and Market Trends
- Market expansion driven by increased screening.
- Ongoing trials for expanded indications.
- Patent restrictions in key markets extend expiry into the late 2020s.
Price Projections
Assumptions
- Market penetration grows at 2-3% annually through 2030.
- Pricing stability or minor decrease due to biosimilar entry planned for 2025.
- Manufacturing and distribution costs stable, keeping gross margins high.
Price Dynamics Forecast
| Year |
Estimated Price per Injection |
Basis for Projection |
Notes |
| 2023 |
$1,850 |
Current price |
Stable pricing based on competitive positioning. |
| 2025 |
$1,680 |
Slight price decrease |
Entry of biosimilars or biosimilar competition expected, reducing price by approximately 10-15%. |
| 2027 |
$1,500 |
Further reduction |
Market saturation plus patent expiries encourage price adjustments. |
| 2030 |
$1,350 |
Market stabilization |
Competition and biosimilar market influence steady prices. |
Revenue Projections
Assuming:
- 20,000 annual treated patients in the U.S.
- Average injections per patient: 7 (initial 3 monthly doses, followed by as-needed dosing)
- Market share increase to 25% by 2030.
Projected U.S. revenue (2023–2030):
| Year |
Patients |
Injections |
Average Price |
Revenue (USD millions) |
| 2023 |
10,000 |
70,000 |
$1,850 |
$129.5 |
| 2025 |
12,500 |
87,500 |
$1,680 |
$146.7 |
| 2027 |
15,000 |
105,000 |
$1,500 |
$157.5 |
| 2030 |
20,000 |
140,000 |
$1,350 |
$189.0 |
International markets will gradually contribute, adding an estimated 30% to annual revenues by 2030.
Key Drivers of Market Growth
- Increasing aging population.
- Rising prevalence of AMD.
- Preference for less frequent dosing regimens.
- Ongoing clinical trials for other ocular indications.
Risks and Challenges
- Biosimilar development, potentially reducing pricing.
- Clinical safety concerns, such as intraocular inflammation.
- Regulatory delays or restrictions in emerging markets.
- Reimbursement pressures.
Final Remarks
Brolucizumab (NDC 71288-0503) is positioned as a high-value anti-VEGF therapy with potential for incremental market share growth, particularly driven by its dosing advantages. Price projections suggest a gradual decline due to biosimilar competition but limited impact on overall revenue growth due to its current market penetration and evolving therapeutic landscape.
Key Takeaways
- The drug faces moderate market share growth driven by clinical advantages over competitors.
- Price per injection is projected to decline approximately 25-30% from current levels by 2030.
- Revenue growth remains robust due to increased treatment adoption and patient population.
- Biosimilar competition will influence pricing post-2025.
- International expansion will be critical for long-term revenue growth.
FAQs
1. How does Brolucizumab compare clinically to other anti-VEGF therapies?
It offers comparable efficacy with the benefit of less frequent dosing, which improves patient adherence.
2. When are biosimilars expected in the market?
Potential biosimilars could enter by 2025, subject to regulatory approval and patent litigation.
3. What are the primary regulatory risks?
Safety concerns such as intraocular inflammation may lead to additional warnings or restrictions.
4. Which markets are most promising for expansion?
Europe, Asia, and Latin America are key targets for international growth.
5. How will reimbursement policies affect prices?
Reimbursement pressures may lower prices or limit pricing increases, especially in publicly funded healthcare systems.
References
[1] Grand View Research. (2022). Age-Related Macular Degeneration Market Size, Share & Trends Analysis.
[2] FDA. (2019). Document on Beovu (brolucizumab) approval and clinical data.
[3] IQVIA. (2022). US Ophthalmic Injectables Market Insights.
[4] Novartis. (2023). Beovu prescribing information.
